Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 093 JPY -0.94%
Market Cap: 6.5T JPY
Have any thoughts about
Takeda Pharmaceutical Co Ltd?
Write Note

Takeda Pharmaceutical Co Ltd
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Takeda Pharmaceutical Co Ltd
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Takeda Pharmaceutical Co Ltd
TSE:4502
Other Non-Cash Items
ÂĄ174.3B
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
37%
Daiichi Sankyo Co Ltd
TSE:4568
Other Non-Cash Items
-ÂĄ25.5B
CAGR 3-Years
-100%
CAGR 5-Years
N/A
CAGR 10-Years
9%
Otsuka Holdings Co Ltd
TSE:4578
Other Non-Cash Items
ÂĄ214.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
64%
S
Shionogi & Co Ltd
TSE:4507
Other Non-Cash Items
-ÂĄ44B
CAGR 3-Years
-28%
CAGR 5-Years
N/A
CAGR 10-Years
-15%
Chugai Pharmaceutical Co Ltd
TSE:4519
Other Non-Cash Items
ÂĄ101.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Other Non-Cash Items
ÂĄ70.7B
CAGR 3-Years
-15%
CAGR 5-Years
71%
CAGR 10-Years
4%
No Stocks Found

Takeda Pharmaceutical Co Ltd
Glance View

Market Cap
6.5T JPY
Industry
Pharmaceuticals

Takeda Pharmaceutical Co. Ltd. stands as a formidable player in the global healthcare landscape, firmly established as Japan's largest pharmaceutical company. Founded in 1781, Takeda has built a rich legacy of innovation and patient-centricity, evolving from a traditional medicine distributor into a leader in biopharmaceuticals. The company primarily focuses on therapeutic areas such as oncology, gastroenterology, neuroscience, and rare diseases, thus targeting critical health challenges faced by patients worldwide. Takeda's commitment to research and development, underscored by significant investments, facilitates the discovery of new treatments and the enhancement of existing therapies. This forward momentum is particularly noteworthy as it aligns with the growing demand for advanced medications and biologics, positioning Takeda favorably in a competitive market. In recent years, Takeda has strategically expanded its global footprint through key acquisitions, most notably the purchase of Shire in 2019, which significantly enhanced its portfolio in rare diseases. For investors, this positions Takeda not just as a pharmaceutical giant, but as an agile and innovative entity eager to meet the evolving needs of healthcare. With a robust pipeline that promises a mix of newly launched therapeutics and a focus on sustainable growth, Takeda showcases its resilience in navigating the pharmaceutical industry's challenges. The company's dedication to fostering partnerships, along with its ethical approach to business, further strengthens its reputation as a trustworthy investment in the pharmaceutical sector. For investors looking for a blend of historical stability and future potential in a company deeply committed to health and well-being, Takeda stands out as a compelling choice.

Intrinsic Value
5 344.29 JPY
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Takeda Pharmaceutical Co Ltd's Other Non-Cash Items?
Other Non-Cash Items
174.3B JPY

Based on the financial report for Sep 30, 2024, Takeda Pharmaceutical Co Ltd's Other Non-Cash Items amounts to 174.3B JPY.

What is Takeda Pharmaceutical Co Ltd's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
37%

Over the last year, the Other Non-Cash Items growth was -61%.

Back to Top